- Report
- September 2026
- 196 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 184 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 180 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 192 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 199 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- January 2026
- 182 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- January 2026
- 183 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- July 2026
- 400 Pages
Global
From €7260EUR$7,990USD£6,241GBP
- Report
- April 2026
- 225 Pages
Global
From €7260EUR$7,990USD£6,241GBP
- Report
- July 2026
- 115 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- April 2026
- 91 Pages
Global
From €3500EUR$4,126USD£3,114GBP
- Report
- May 2024
- 200 Pages
Global
From €3771EUR$4,150USD£3,242GBP
- Report
- September 2021
- 111 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1817EUR$2,000USD£1,562GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1363EUR$1,500USD£1,172GBP
- Report
- July 2024
- 231 Pages
Global
From €7224EUR$7,950USD£6,210GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2499EUR$2,750USD£2,148GBP

Certolizumab is a monoclonal antibody used to treat immune disorders. It is used to treat a variety of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. It works by blocking the action of a protein called tumor necrosis factor (TNF), which is involved in the body's inflammatory response. Certolizumab is administered as an injection, usually once every two weeks.
Certolizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is one of several drugs used to treat immune disorders, and is often used in combination with other medications. It is generally well-tolerated, with few side effects.
Some companies in the Certolizumab market include UCB, Pfizer, and AbbVie. Show Less Read more